Kushnir Vitaly A, Barad David H, Albertini David F, Darmon Sarah K, Gleicher Norbert
The Center for Human Reproduction, 21 East 69th Street, New York, NY, 10021, USA.
Wake Forest School of Medicine, Winston-Salem, NC, USA.
Reprod Biol Endocrinol. 2017 Jan 10;15(1):6. doi: 10.1186/s12958-016-0225-2.
Assisted Reproductive Technology (ART) has undergone considerable changes over the last decade, with consequences on ART outcomes in different regions of the world being unknown.
We conducted a systematic review of published national and regional ART registry data to assess how changes in clinical practice between 2004 and 2013 have impacted outcomes in Australia and New Zealand, Canada, Continental Europe, the United Kingdom (U.K.), Japan, Latin America, and the United States (U.S.). The data reflect 7,079,145 total ART cycles utilizing both fresh and previously cryopreserved embryos from autologous oocytes that resulted in 1,454,724 live births. This review focused on the following measures: ART cycle volume, use of cryopreserved embryos, single embryo transfer (SET), live birth rates in fresh and frozen-thawed cycles, and perinatal outcomes in recent years.
SETs and utilization of frozen-thawed embryos increased worldwide over the study period. In 2012 SET utilization in all ART cycles was highest in Japan and Australia/New Zealand (82.6% and 76.3% respectively) and lowest in Latin America (16.0%). While gradual improvements in live birth rates were observed in most regions, some demonstrated declines. By 2012-2013, fresh cycle live birth rates were highest in the U.S. (29%) and lowest in Japan (5%). In Japan, the observed decline in fresh cycle live birth rate coincided with transition to minimal stimulation protocols, transfer of frozen-thawed rather than fresh embryos, and implementation of an SET policy. Similarly, implementation of an SET policy in parts of Canada was followed by a decline in fresh cycle live birth rate. Increasing live birth rates in frozen-thawed embryo cycles, seen all over the world, partially compensated for declines in fresh ART cycles. During 2012-2013 Australia/New Zealand and Japan reported the lowest multiple delivery rates of 5.6 and 4% respectively while the US had the highest of 27%. In recent years, preterm delivery rates in all regions ranged between 9.0 to 16.6% for singletons, 53.9 to 67.3% for twins, and 91.4 to 100% for triplets and higher order multiples. Inconsistencies in the way perinatal outcome data are presented by various registries, made comparison between regions difficult.
ART practices are characterized by outcome differences between regions. International consensus on the definition of ART success, which accounts for perinatal outcomes, may help to standardize worldwide ART practice and improve outcomes.
PROSPERO ( CRD42016033011 ).
在过去十年中,辅助生殖技术(ART)发生了重大变化,其对世界不同地区ART结局的影响尚不清楚。
我们对已发表的国家和地区ART登记数据进行了系统评价,以评估2004年至2013年临床实践的变化如何影响澳大利亚和新西兰、加拿大、欧洲大陆、英国、日本、拉丁美洲及美国的结局。数据反映了总共7079145个ART周期,这些周期使用了来自自体卵母细胞的新鲜和先前冷冻保存的胚胎,共产生了1454724例活产。本评价重点关注以下指标:ART周期数量、冷冻保存胚胎的使用、单胚胎移植(SET)、新鲜周期和冻融周期的活产率以及近年来的围产期结局。
在研究期间,全球范围内SET和冷冻解冻胚胎的利用率有所增加。2012年,日本和澳大利亚/新西兰在所有ART周期中的SET利用率最高(分别为82.6%和76.3%),拉丁美洲最低(16.0%)。虽然大多数地区的活产率有逐步提高,但有些地区出现了下降。到2012 - 2013年,美国新鲜周期活产率最高(29%),日本最低(5%)。在日本,新鲜周期活产率的下降与向最小刺激方案的转变、冷冻解冻胚胎而非新鲜胚胎的移植以及SET政策的实施相吻合。同样,加拿大部分地区实施SET政策后,新鲜周期活产率下降。世界各地冷冻解冻胚胎周期活产率的增加部分抵消了新鲜ART周期的下降。2012 - 2013年期间,澳大利亚/新西兰和日本的多胎分娩率最低,分别为5.6%和4%,而美国最高,为27%。近年来,所有地区单胎的早产率在9.0%至16.6%之间,双胎为53.9%至67.3%,三胎及以上多胎为91.4%至100%。各登记处呈现围产期结局数据的方式不一致,使得地区间的比较变得困难。
ART实践的特点是地区间结局存在差异。就ART成功的定义达成国际共识,其中考虑围产期结局,可能有助于规范全球ART实践并改善结局。
PROSPERO(CRD42016033011)